Skip to main content
. 2022 Aug 3;27(10):809–e765. doi: 10.1093/oncolo/oyac155

Figure 1.

Figure 1.

Progression-free survival (N = 10). The overall mPFS for all subjects included in the trial was 5.4 months. The mPFS was 3.8 months in subjects with prior anthracycline treatment and 8.2 months for subjects without prior anthracycline treatment.